Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting

Long Term Follow Up Data from Phase 1 ALPHA/ALPHA2 Trials Demonstrate Potential of Allogeneic CD19 CAR T to Generate Durable Complete Responses Similar to Approved Autologous Therapies Presentation... | June 3, 2023

Related Keywords

Chicago ,Illinois ,United States ,American ,Allogene Allo ,Madeleine Goldstein ,Zachary Roberts ,Christine Cassiano ,Linkedin ,American Society Of Clinical Oncology ,European Hematology Association ,Nasdaq ,Corporate Pipeline Communications ,Allogene Therapeutics Inc ,Research Development ,Drug Administration ,Globenewswire Inc ,Long Term Follow Up Data ,Demonstrate Potential ,Generate Durable Complete Responses Similar ,Approved Autologous ,Overall Response Rate ,Complete Response ,Ongoing Beyond Six Months ,Including Two ,Immune Recovery Comparable ,Cell Expansion ,Persistence Documented ,Treatment Initiated ,Three Days After Enrollment Without Need ,Bridging Therapy ,Received Allogeneic ,Potentially Pivotal Phase ,Expected Completion ,Clinical Oncology ,Annual Meeting ,Hematology Association ,Hybrid Congress ,Executive Vice President ,Chief Medical ,Response Rate ,Regenerative Medicine Advanced Therapy ,San Francisco ,Private Securities Litigation Reform Act ,Investor Contact ,Allogene Media Contact ,Allogene Therapeutics ,Nc Stock Exchange ,News ,Information ,Press Release ,Song ,Term ,Follow ,P ,Data ,Rom ,Hase , ,Trials ,Emonstrate ,Potential ,F ,Allogeneic ,Cvd19 ,Ear ,O ,Enerate ,Durable ,Omplete ,Responses ,Similar ,Approved ,Tautologous ,Herapies Allo Us0197701065 ,